To examine the effects of PKM2 targeting on response to PD-1 blockade and the cytotoxicity of NK cells, we infused NK cells derived from human PBMCs (1 × 106/mice) and/or administered anti-PD-1 (10 mg/kg, 3 of 7 days) to immunodeficient PDAC model where tumor cells were infected with PKM2-shRNA or scramble-shRNA. Here, PKM is linked to neoplasm.